Probiotics reduced incidence of antibiotic-associated diarrhea

  • Infectious Disease News, June 2012

Findings from a recent meta-analysis indicated that probiotics were associated with a 42% decreased risk for developing antibiotic-associated diarrhea.

“Antibiotics do not cause diarrhea in all patients, but it is a known side effect that may even stop some people from finishing a full course of antibiotics,” Susanne Hempel, PhD, of the Southern California Evidence-based Practice Center of RAND Health in Santa Monica, Calif., told Infectious Disease News. 

Susanne Hempel, PhD
Susanne Hempel

Hempel and colleagues conducted the systematic review, which included 82 randomized controlled trials pooled from 12 databases. The studies analyzed the use of probiotics for the prevention or treatment of antibiotic-associated diarrhea. The types of probiotics included Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus and Bacillus.

Across 63 of the randomized trials, the use of probiotics was associated with a lower RR of developing diarrhea when compared with controls (RR=0.58; 95% CI, 0.5-0.68). In 16 randomized trials that only included children, the RR for developing diarrhea after probiotic use was 0.55 (95% CI, 0.38-0.8). In the 14 randomized trials that only included adults aged 18 to 65 years, the RR for developing diarrhea after probiotic use was 0.54 (95% CI, 0.34-0.85).

“We found a beneficial effect of probiotics for antibiotic-associated diarrhea,” Hempel said. “However, more work is needed to determine which probiotic interventions work best, which patients are most likely to benefit, which probiotics work best with which antibiotics and whether there are any risks in using them.”

References:

  • Hempel S. JAMA. 2012;307:1959-1969.

Disclosures:

  • The researchers report no financial disclosures.

Perspective
James P. Nataro, MD

James P. Nataro

  • Diarrhea is the most frequent adverse effect of antibiotic administration. Although it is rarely a serious threat to the child, it does compromise adherence to therapy and will occasionally lead to full-blown colitis. Many pediatricians recommend probiotics or probiotic-containing interventions to prevent or treat antibiotic-associated diarrhea (AAD), although the data to support this practice have heretofore been limited.

    This study by Hempel and coauthors presents a comprehensive review and meta-analysis of studies that utilize probiotics in the prevention and treatment of AAD. In this thorough and well-presented analysis, the authors conclude that probiotics are associated with a significant reduction in AAD. Their conclusion comes as no surprise to pediatricians long accustomed to the use of probiotics for AAD, but there are some messages which warrant consideration.

    It is widely believed that antibiotics cause diarrhea via perturbation of the commensal intestinal microbiota. Accordingly, the administration of abundant constituents of the microbiota carries the weight of biological plausibility. In fact, it is tempting to move beyond the assignment of “probiotic” species, defined as microorganisms that produce health effect when consumed, toward a broader appreciation that our microbiota are in general good for us, and that they should be preserved, protected, characterized, and, yes, reconstituted when and where possible. In keeping with this idea, Hempel and colleagues have found consistent benefit to probiotic administration, regardless of the product consumed, including but not limited to members of the genera Lactobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus and Bacillus. Certainly these species are marketed as probiotic preparations based on pre-clinical and often clinical evidence, but we should not assume that only these species will provide therapeutic or prophylactic benefit.

    Although Hempel and colleagues have confirmed the benefit of probiotics against AAD, the paper does not allow the reader to infer which probiotic formulations to recommend for our patients, or whether it is better to prescribe them prior to the onset of diarrhea. It is intuitive, of course, that probiotic formulations delivering higher titers of live bacteria are more efficacious, but this effect cannot be discerned from the data. Importantly, the meta-analysis approach was required to confirm the benefit of probiotics in AAD because the effect size is modest: the number-needed-to-treat to benefit one patient was 13 for diarrhea, and colitis was not an endpoint of this study. It is therefore left to the practitioner and the family to select their preferred product, and to decide whether the benefits of probiotics warrant the cost and inconvenience of another medication administration. The report by Hempel may stimulate further studies that compare formulations or drive the development of more efficacious preparations.

    • James P. Nataro, MD
    • Benjamin Armistead Shepherd Professor and Chair, Department of Pediatrics, University of Virginia School of Medicine Pediatrician-in-Chief, University of Virginia Children's Hospital, Charlottesville, Va.
  • Disclosures: Dr. Nataro reports no relevant financial disclosures.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]